Descripción del proyecto
Análisis eficiente de datos para la investigación de enfermedades
Uno de los mayores obstáculos en la investigación de enfermedades es la variedad de los datos a la hora de estudiar los mecanismos subyacentes o priorizar las dianas para nuevos tratamientos. Esto da lugar a un bajo rendimiento y calidad. La empresa tecnológica alemana knowing01 ha desarrollado un «software» como servicio que permite al usuario conectarse y explorar los datos de la OMIC independientemente del tipo de datos biológicos. Este innovador método de traducción de datos basado en gráficos de conocimiento permitirá que los científicos lleven a cabo análisis entre tipos de datos y que comparen diferentes conjuntos en su contexto biológico. En el proyecto BInno2scalek01, financiado con fondos europeos, se efectuará una evaluación fundamental de esta tecnología. Aprovechará la posición de nicho de mercado de la tecnología y realizará avances con la infraestructura y las tecnologías relacionadas con bases de datos. BInno2scalek01 se beneficiará de la subvención Women TechEU.
Objetivo
Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.
Ámbito científico
Programa(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-AG-LS - HORIZON Lump Sum GrantCoordinador
81243 MUNCHEN
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.